AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3069479 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg chlorambucil
Number of subjects: 5
Study 3069479 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg chlorambucil
Number of subjects: 5
Study 3069479 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg chlorambucil
Number of subjects: 5
Study 3069479 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenyl acetic acid mustard (metabolite)
Number of subjects: 5
Study 3069479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-corrected AUC for chlorambucil
Number of subjects: 5
Study 3069479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-corrected AUC for metabolite
Number of subjects: 5
Study 3069479 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil and metabolite
Number of subjects: 5
Study 31509072 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Mothers and Schools (Project MAS)
Number of subjects: 84
Study 31008545 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 g MMT/kg
Number of subjects: 480
Study 31008545 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g MMT/kg
Number of subjects: 480
Study 31008545 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g MMT/kg
Number of subjects: 480
Study 31008545 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g MMT/kg
Number of subjects: 480
Study 31008545 — intervention group
Group type: EXPERIMENTAL
Intervention: MMT supplementation
Number of subjects: 480
Study 28783464 — intervention group
Group type: EXPERIMENTAL
Intervention: MLS laser therapy and exercises
Number of subjects: 75
Study 28783464 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT and exercises
Number of subjects: 75
Study 28783464 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser therapy plus exercises (PL + EX)
Number of subjects: 75
Study 25217123 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg i.v.)
Number of subjects: 40
Study 22716148 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 10 mg
Number of subjects: 16
Study 22716148 — intervention group
Group type: COMPARATOR
Intervention: CBD 600 mg
Number of subjects: 16
Study 22716148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20083523 — intervention group
Group type: EXPERIMENTAL
Intervention: Play Nicely educational program (intervention group, n = 130)
Number of subjects: 259
Study 20083523 — intervention group
Group type: EXPERIMENTAL
Intervention: Play Nicely educational program (intervention group, n = 59 Spanish-speaking caregivers)
Number of subjects: 259
Study 20083523 — intervention group
Group type: EXPERIMENTAL
Intervention: Play Nicely educational program (intervention group)
Number of subjects: 259
Study 20083523 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group, n = 129)
Number of subjects: 259
Study 20083523 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 259
Study 17438314 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (40 mg of pantoprazole, 1 g of amoxicillin, and placebo for the first 5 days, followed by 40 mg of pantoprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days)
Number of subjects: 300
Study 17438314 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (40 mg of pantoprazole, 500 mg of clarithromycin, and 1 g of amoxicillin, each administered twice daily for 10 days)
Number of subjects: 300
Study 17438314 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 300
Study 17438314 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 300
Study 17438314 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 300
Study 15627534 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of naloxone (1.2 mg over 48 h) and morphine (6 mg over 48 h) in 0.1% bupivacaine
Number of subjects: 58
Study 15627534 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural morphine (6 mg over 48 h) in 0.1% bupivacaine
Number of subjects: 58
Study 12131417 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral lumbar fusion with Cotrel‐Dubousset instrumentation
Number of subjects: 130
Study 12131417 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral lumbar fusion without instrumentation
Number of subjects: 130
Study 12131417 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (instrumented and noninstrumented)
Number of subjects: 130
Study 10205983 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-containing toothpaste (CAOLA)
Number of subjects: 0
Study 10205983 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-containing dentifrices
Number of subjects: 0
Study 10205983 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-containing dentifrices
Number of subjects: 0
Study 7955179 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline D-dimer concentration exceeding the 95th percentile of the control distribution
Number of subjects: 296
Study 2636388 — intervention group
Group type: EXPERIMENTAL
Intervention: Variants of the English rise‐fall‐rise pattern
Number of subjects: 0
Study 2636388 — intervention group
Group type: EXPERIMENTAL
Intervention: LPC resynthesis stimuli with varying F0 rise‐fall alignment
Number of subjects: 0
Study 1099172 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine HCl (1 mg) administered subcutaneously three times a day for 14 days
Number of subjects: 40
Study 1099172 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (placebo) administered subcutaneously three times a day for 14 days
Number of subjects: 40
Study 31065841 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency intensive balneotherapy (3 weeks)
Number of subjects: 236
Study 31065841 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency balneotherapy followed by land-based exercise (3 weeks of each)
Number of subjects: 236
Study 28952295 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin and clavulanate potassium
Number of subjects: 146
Study 28952295 — intervention group
Group type: COMPARATOR
Intervention: Ceftezole sodium
Number of subjects: 146
Study 25649019 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0
Study 25649019 — intervention group
Group type: COMPARATOR
Intervention: PTEN status
Number of subjects: 0
Study 22917440 — intervention group
Group type: EXPERIMENTAL
Intervention: Beyond + artificial saliva (AS)
Number of subjects: 108
Study 22917440 — intervention group
Group type: EXPERIMENTAL
Intervention: Beyond + distilled water (DW)
Number of subjects: 108
Study 22917440 — intervention group
Group type: COMPARATOR
Intervention: Control + HS
Number of subjects: 108
Study 22917440 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence Boost (O‐Boost) + HS
Number of subjects: 108
Study 22917440 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence Boost (O‐Boost) + AS
Number of subjects: 108
Study 22917440 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence Boost (O‐Boost) + DW
Number of subjects: 108
Study 22917440 — intervention group
Group type: EXPERIMENTAL
Intervention: Beyond + HS
Number of subjects: 108
Study 22917440 — intervention group
Group type: COMPARATOR
Intervention: Control + AS
Number of subjects: 108
Study 22917440 — intervention group
Group type: COMPARATOR
Intervention: Control + DW
Number of subjects: 108
Study 21566113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium thiosulfate (STS)
Number of subjects: 19
Study 21566113 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium thiosulfate (STS)
Number of subjects: 19
Study 19232560 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser arcuate keratotomy (AK)
Number of subjects: 20
Study 19232560 — intervention group
Group type: COMPARATOR
Intervention: Mechanized arcuate keratotomy (AK)
Number of subjects: 20
Study 16549458 — intervention group
Group type: EXPERIMENTAL
Intervention: L-[1-(13C)]-leucine oxidation measured after a primed, continuous oral administration of the tracer in the postabsorptive state
Number of subjects: 21
Study 16549458 — intervention group
Group type: EXPERIMENTAL
Intervention: L-[1-(13C)]-leucine oxidation measured after a primed, continuous oral administration of the tracer in the fed state
Number of subjects: 21
Study 14514224 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap with enamel matrix derivative (EMD)
Number of subjects: 20
Study 14514224 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap with subepithelial connective tissue graft
Number of subjects: 20
Study 10699322 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-125 microg rPspA
Number of subjects: 0
Study 10699322 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-immune sera
Number of subjects: 0
Study 10699322 — intervention group
Group type: EXPERIMENTAL
Intervention: Human anti-rPspA
Number of subjects: 0
Study 9327194 — intervention group
Group type: EXPERIMENTAL
Intervention: rifaximin 400 mg three times daily
Number of subjects: 49
Study 9327194 — intervention group
Group type: COMPARATOR
Intervention: neomycin 1 g three times daily
Number of subjects: 49
Study 8268780 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral-based interventions to help women overcome personal barriers
Number of subjects: 663
Study 8268780 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive orientation measured by smoking status
Number of subjects: 663
Study 8268780 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about mammography
Number of subjects: 663
Study 8268780 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty getting to the screening center
Number of subjects: 663
Study 2870223 — intervention group
Group type: EXPERIMENTAL
Intervention: InterVir-A (IVA)
Number of subjects: 69
Study 2870223 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 69
Study 31898766 — intervention group
Group type: EXPERIMENTAL
Intervention: ASL alone
Number of subjects: 24
Study 31898766 — intervention group
Group type: EXPERIMENTAL
Intervention: All sequences including 4D CE MRA
Number of subjects: 24
Study 30140071 — intervention group
Group type: EXPERIMENTAL
Intervention: Reticulocyte hemoglobin content (Ret‐He) measured at birth (umbilical cord sample)
Number of subjects: 456
Study 30140071 — intervention group
Group type: EXPERIMENTAL
Intervention: Reticulocyte hemoglobin content (Ret‐He) measured at 48-72 hours
Number of subjects: 456
Study 30140071 — intervention group
Group type: EXPERIMENTAL
Intervention: Reticulocyte hemoglobin content (Ret‐He) measured at 4 months
Number of subjects: 456
Study 30140071 — intervention group
Group type: EXPERIMENTAL
Intervention: Reticulocyte hemoglobin content (Ret‐He) measured at 12 months
Number of subjects: 456
Study 26424731 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise for 16 weeks
Number of subjects: 69
Study 26424731 — intervention group
Group type: COMPARATOR
Intervention: Counselling without dietary modification for 16 weeks
Number of subjects: 69
Study 25799848 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking smelters
Number of subjects: 166
Study 25799848 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers smoking ≥20 cigarettes per day
Number of subjects: 166
Study 25799848 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking smelters
Number of subjects: 166
Study 25799848 — intervention group
Group type: COMPARATOR
Intervention: Control group (unexposed subjects)
Number of subjects: 166
Study 22984150 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral blockade (PVB) with ropivacaine
Number of subjects: 40
Study 22984150 — intervention group
Group type: COMPARATOR
Intervention: Surgical infiltration of ropivacaine
Number of subjects: 40
Study 20863008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine hydrochloride 10 mg p.o.
Number of subjects: 12
Study 20863008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine hydrochloride 20 mg p.o.
Number of subjects: 12
Study 20863008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine hydrochloride 30 mg p.o.
Number of subjects: 12
Study 20863008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine hydrochloride 10 mg i.m.
Number of subjects: 12
Study 19127824 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anxiety-state
Number of subjects: 83
Study 19127824 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anxiety-trait
Number of subjects: 83
Study 16003055 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 4 microg/kg/min for 6 hrs
Number of subjects: 60
Study 16003055 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 8 microg/kg/min for 6 hrs
Number of subjects: 60
Study 16003055 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 60
Study 12091844 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rhEPO (750 IU/kg/week for 9 weeks)
Number of subjects: 219
Study 12091844 — intervention group
Group type: EXPERIMENTAL
Intervention: Late rhEPO (750 IU/kg/week for 6 weeks)
Number of subjects: 219
Study 12091844 — intervention group
Group type: COMPARATOR
Intervention: Control (no rhEPO)
Number of subjects: 219
Study 10483821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 24 mg q.d.
Number of subjects: 357
Study 10483821 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 8 mg b.i.d.
Number of subjects: 357
Study 10483821 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 32 mg q.d.
Number of subjects: 357
Study 8694672 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of intramuscular ketorolac tromethamine
Number of subjects: 30
Study 8694672 — intervention group
Group type: COMPARATOR
Intervention: 25 mg of intravenous chlorpromazine hydrochloride
Number of subjects: 30
Study 1928881 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen (5 mg hydrocodone with 500 mg acetaminophen)
Number of subjects: 50
Study 1928881 — intervention group
Group type: COMPARATOR
Intervention: Codeine/acetaminophen (30 mg codeine with 500 mg acetaminophen)
Number of subjects: 50
Study 1928881 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen
Number of subjects: 50
Study 1928881 — intervention group
Group type: COMPARATOR
Intervention: Codeine/acetaminophen
Number of subjects: 50
Study 7154835 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (NLX) 0.4 mg i.v.
Number of subjects: 22
Study 7154835 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 22
Study 30724666 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry-based randomized clinical trials
Number of subjects: 0
Study 30724666 — intervention group
Group type: EXPERIMENTAL
Intervention: TASTE study
Number of subjects: 0
Study 28333511 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person brief alcohol intervention (BAI)
Number of subjects: 961
Study 28333511 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based brief alcohol intervention (BAI)
Number of subjects: 961
Study 28333511 — intervention group
Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 961
Study 26547700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba dry extract (120mg/day)
Number of subjects: 58
Study 26547700 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐lipoic acid (60mg/day)+vitamin C (600mg/day)
Number of subjects: 58
Study 26547700 — intervention group
Group type: EXPERIMENTAL
Intervention: papaverine hydrochloride (100mg/day)+vitamin E (400mg/day)
Number of subjects: 58
Study 26547700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 24886066 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein testing (CRP) in the intervention group
Number of subjects: 179
Study 24886066 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CRP testing)
Number of subjects: 179
Study 21284552 — intervention group
Group type: EXPERIMENTAL
Intervention: Crestal implant placement
Number of subjects: 24
Study 21284552 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcrestal implant placement
Number of subjects: 24
Study 21284552 — intervention group
Group type: COMPARATOR
Intervention: Crestal and Subcrestal implant placement
Number of subjects: 24
Study 20228003 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO₄ 6.4% (2.5 mL) administered in 3 nebulisations at 30 minute intervals
Number of subjects: 13
Study 20228003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 17872451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (270 mg/dL)
Number of subjects: 78
Study 17872451 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 78
Study 15000508 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood condition
Number of subjects: 302
Study 15000508 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral mood condition
Number of subjects: 302
Study 15000508 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood condition
Number of subjects: 302
Study 15000508 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking motives
Number of subjects: 302
Study 15000508 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 302
Study 11720177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar (verum challenge)
Number of subjects: 30
Study 11720177 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo challenge)
Number of subjects: 30
Study 9164228 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dolasetron 200 mg and oral dexamethasone 20 mg (one-dose regimen)
Number of subjects: 75
Study 9164228 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dolasetron 200 mg and oral dexamethasone 20 mg (two-dose regimen)
Number of subjects: 75
Study 9164228 — intervention group
Group type: EXPERIMENTAL
Intervention: One-dose regimen
Number of subjects: 75
Study 9164228 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose regimen
Number of subjects: 75
Study 7957541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg)
Number of subjects: 151
Study 7957541 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine (16 g)
Number of subjects: 151
Study 7957541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg combined with cholestyramine (4 g)
Number of subjects: 151
Study 7957541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg combined with cholestyramine (8 g)
Number of subjects: 151
Study 7957541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg combined with cholestyramine (16 g)
Number of subjects: 151
Study 7957541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin and Cholestyramine (all doses)
Number of subjects: 151
Study 3608372 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate administration (5 mmol of calcium chloride and 21 mmol of citrate in the form of sodium potassium citrate)
Number of subjects: 8
Study 3608372 — intervention group
Group type: COMPARATOR
Intervention: Citrate-free vehicle load
Number of subjects: 8
Study 29125655 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 1000
Study 26794937 — intervention group
Group type: EXPERIMENTAL
Intervention: Convers Plus 4/1.25 mg Tablet (test)
Number of subjects: 24
Study 26794937 — intervention group
Group type: COMPARATOR
Intervention: Bipreterax 4/1.25 mg Tablet (reference)
Number of subjects: 24
Study 25886226 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (0.075 mg)
Number of subjects: 120
Study 25886226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 120
Study 25886226 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (2 mg)
Number of subjects: 120
Study 22777579 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic teaching
Number of subjects: 20
Study 22777579 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic learning
Number of subjects: 20
Study 22777579 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline)
Number of subjects: 20
Study 20478332 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based prevention activities (intervention)
Number of subjects: 5024
Study 20478332 — intervention group
Group type: COMPARATOR
Intervention: Control communities (non-intervention)
Number of subjects: 5024
Study 17080003 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (100 microg)
Number of subjects: 32
Study 17080003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17080003 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (100 microg)
Number of subjects: 32
Study 16227761 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40-80 mg daily plus hydrochlorothiazide 12.5 mg daily (if needed)
Number of subjects: 1469
Study 11953670 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy (epoetin-alpha)
Number of subjects: 0
Study 10441604 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 59
Study 10441604 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 59
Study 10441604 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Phenobarbital first)
Number of subjects: 59
Study 10441604 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Phenytoin first)
Number of subjects: 59
Study 7476282 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-fat diet (LCD)
Number of subjects: 10
Study 2181334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 2 mg/h
Number of subjects: 204
Study 2181334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 3 mg/h
Number of subjects: 204
Study 2181334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (both doses) in patients with Hunt and Hess grades IV or V
Number of subjects: 204
Study 2181334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (both doses) in patients with Hunt and Hess grades I to III
Number of subjects: 204
Study 473853 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Metoprolol
Number of subjects: 9
Study 473853 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg Pindolol
Number of subjects: 9
Study 473853 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study 30536405 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (1.8 mg m-2 per cycle)
Number of subjects: 250